@RheumNow’s review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI
TO THE NEW MONTHLY EMAIL
Reader Type Rheumatologist Patient or Concerned Individual Media/Press Other Healthcare Professional Other Physician Pharmaceutical Industry or Biotech Individual Pharmacist Physician Assistant, Nurse Practitioner, Rheumatology Nurse Primary Physician Trainee (Fellow, Resident, Student)
Monthly Topic Digests (Choose one or many) Autoinflammatory & Still's Disease (via StillsNow)
Email address: